Bosutinib for Successful Treatment-Free Remission in Chronic Myeloid Leukemia.

ABSTRACT:

Introduction and objective

This study explored the status of patients with chronic myeloid leukemia following the safe discontinuation of frontline or second-line bosutinib treatment. The goal was to assess the long-term outcomes and factors influencing treatment-free remission (TFR) following cessation of bosutinib therapy.

Methods

The median duration of bosutinib treatment among 16 patients was 48 months. All patients achieved a deep molecular response before bosutinib discontinuation, which was sustained for a median pre-cessation period of 27 months. Patients were monitored for molecular response and clinical outcomes.

Results

After bosutinib discontinuation, the major molecular response was lost in six patients: within 6 months in five patients and at 19 months i

SUBMITTER: Fujioka Y 

PROVIDER: S-EPMC12037706 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature